Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Standard BioTools Inc. before investing.

In this article, we go over a few key elements for understanding Standard BioTools Inc.’s stock price such as:

• Standard BioTools Inc.’s current stock price and volume
• Why Standard BioTools Inc.’s stock price changed recently
• Upgrades and downgrades for LAB from analysts
• LAB’s stock price momentum as measured by its relative strength

About Standard BioTools Inc. (LAB)

Before we jump into Standard BioTools Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates in two segments, Proteomics and Genomics. Its proteomics and genomics include instruments, consumables, software, and services based upon technologies used in the identification of proteins, as well as genes and their functions. The company provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in April 2022. Standard BioTools Inc. was incorporated in 1999 and is headquartered in South San Francisco, California.

Want to learn more about Standard BioTools Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Standard BioTools Inc..

Standard BioTools Inc.’s Stock Price as of Market Close

As of June 11, 2025, 12:47 PM, CST, Standard BioTools Inc.’s stock price was $1.100.

Standard BioTools Inc. is up 1.85% from its previous closing price of $1.080.

During the last market session, Standard BioTools Inc.’s stock traded between $1.090 and $1.120. Currently, there are approximately 378.23 million shares outstanding for Standard BioTools Inc..

Standard BioTools Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Standard BioTools Inc. Stock Price History

Standard BioTools Inc.’s (LAB) price is currently up 8.91% so far this month.

During the month of June, Standard BioTools Inc.’s stock price has reached a high of $1.130 and a low of $0.984.

Over the last year, Standard BioTools Inc. has hit prices as high as $2.450 and as low as $0.920. Year to date, Standard BioTools Inc.’s stock is down 37.14%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Standard BioTools Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 10, 2025, there were 0 analysts who downgraded Standard BioTools Inc.’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Standard BioTools Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Standard BioTools Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Standard BioTools Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Standard BioTools Inc. (LAB) by visiting AAII Stock Evaluator.

Relative Price Strength of Standard BioTools Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 10, 2025, Standard BioTools Inc. has a weighted four-quarter relative price strength of -18.20%, which translates to a Momentum Score of 10 and is considered to be Very Weak.

Want to learn more about how Standard BioTools Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Standard BioTools Inc. Stock Price: Bottom Line

As of June 11, 2025, Standard BioTools Inc.’s stock price is $1.100, which is up 1.85% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Standard BioTools Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.